LY03004, Luye Pharma’s innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market. The company has announced that i...
Since its establishment in 1994, Luye Life Sciences has expanded from the shore of the Yellow Sea in Yantai to Singapore, the United States, Germany, Japan, and Australia...and its staff has grown fro...
In following with the Chinese government’s call to "Promote the modernization of traditional Chinese medicine (TCM) and promote TCM to the world", as well as the Chinese government&rsq...
On March 23, 2019, the Development Research Center of the State Council hosted the “Economic Summit of China Development Forum 2019” at the Diaoyutai State Guesthouse in Beijing. The theme of this y...
On April 26, Luye Pharma Group announced an agreement with Pharma Mar S.A (“PharmaMar”) to develop and commercialize a Phase III new innovative anti-cancer drug: Zepsyre® (Lurbinectedin).According t...
From August 28 to 31, the 17th National Congress of Psychiatry (CSP2019) of the Chinese Medical Association was held in Nanjing. The conference brought together experts and scholars from around the wo...
Luye Pharma Group (02186.HK) released its financial results for the first half of 2019 on August 28. The results show the company has achieved a revenue of RMB 3.131 billion, up 42.1% year-on-year; EB...
Luye Pharma has announced that it has entered an agreement with AstraZeneca, the terms of which grant the latter exclusive rights to promote Luye Pharma’s natural lipid-regulating drug Xuezhikan...
One of Luye Medical's subsidiaries, Healthe Care,has been voted via independent survey of more than 10,860 Australians, the 12th best company to work for in Australia.The result is part of Randsta...
Luye Pharma Group announced today that the pivotal study for Rivastigamine Multi-Day Transdermal Patch (Rivastigamine MD), an innovative delivery system drug for the treatment of Alzheimer’s dis...
TOP